Are estrogens carcinogens?;Sind estrogene karzinogene?

Journal fur Menopause

Volumn 9, Issue 2, 2002, Pages 20-29

  Kuhl, H ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COUMESTROL; DAIDZEIN; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GENISTEIN; MESTRANOL;

BREAST CANCER; CANCER GRADING; CANCER RISK; CARCINOGENESIS; GENOTOXICITY; HORMONAL CONTRACEPTION; MENSTRUAL CYCLE; REVIEW;

EID: 0036965321     PISSN: 10230904     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Twombly R. Federal carcinogen report debuts new list of nominees. J Natl Cancer Inst 2001; 93: 1372.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1998; 347: 1713-27.
3. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-59.
4. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. Br Med J 1996; 312: 1646-7.
5. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449-57.
6. Helzlsouer KJ, Couzi R. Hormones and breast cancer. Cancer 1995; 76: 2059-63.
7. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treatm 1999; 54: 117-22.
8. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Ass 2000; 283: 485-91.
9. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-32.
10. Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58: 163-70.
11. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559-65.
12. Persson I, Adami HO, Bergkvist L, Lindgren A, Petterson B, Hoover R, Schairer C. Risk of endometrial cancer treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 1989; 298: 147-51.
13. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13.
14. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement therapy with and without progestins. J Natl Cancer Inst 1999; 91: 1131-7.
15. Zichella L. HRT and endometrial cancer. Menopause Rev 1997; 2: 18-25.
16. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 1110-6.
17. Kuhl H, Jung-Hoffmann C. Kontrazeption. Thieme Verlag, Stuttgart, 1999; 80-1.
18. Burger CW, Koomen I, Peters NAJB, van Leeuwen FE, Kenemans P. Postmenopausal hormone replacement therapy and cancer of the female genital tract and the breast. Eur Menopause J 1997; 4: 23-36.
19. Whittemore AS, Harris R, Intyre J and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Am J Epidemiol 1992; 136: 1184-203.
20. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94: 32-8.
21. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-32.
22. LaVecchia C. HRT and the risk of neoplasms other than the breast. Eur Menopause J 1996; 3: 232-6.
23. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and metaanalysis. Am J Med 1999; 106: 574-82.
24. Nanda K, Bastin LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880-8.
25. Kuhl H, Jung-Hoffmann C. Kontrazeption. Thieme Verlag, Stuttgart, 1999; 83.
26. Taubert HD, Kuhl H. Kontrazeption mit Hormonen. Thieme Verlag, Stuttgart, 1995; 105-9.
27. McCann J, Choi E, Yamasaki E, Ames BN. Detection of carcinogens as mutagens in the salmonella/microsome test: assay of 300 chemicals. Proc Natl Acad Sci USA 1975; 72: 5135-9.
28. Kommission Hormontoxikologie der Deutschen Gesellschaft für Endokrinologie: Karzinogene Eigenschaften von Estradiol-17β? (Entwurf: Zimmermann H, Kuhl H). Endokrinologie Informationen 2000; 24: 181-6.
29. Seibert B, Günzel P. Animal toxicity studies performed for risk assessment of the once-a-month injectable contraceptive mesigynar®. Contraception 1994; 49: 303-33.
30. Lang R, Reimann R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. 1. Communication: examination for the induction of gene mutations using the Ames salmonella/microsome test and the HPGRT test in V79 cells. Environ Mol Mutagen 1993; 21: 272-304.
31. Hundal BS, Dhillon VS, Sidhu IS. Genotoxic potential of estrogens. Mutat Res 1997; 389: 173-81.
32. Dhillon VS, Dhillon IK. Genotoxicity evaluation of estradiol. Mutat Res-Genetic Toxicol 1995; 345: 87-95.
33. Dhillon VS, Singh JR, Singh H, Kler RS. In vitro and in vivo genotoxicity evaluation of hormonal drugs v mestranol. Mutat Res-Genetic Toxicol 1994; 322: 173-83.
34. Itoh S, Matsuura Y, Seki H, Tazawa T, Shimada H. Mutagenicity studies of norethisterone and ethinylestradiol. Yakuri to chiryo 1991; 19 (Suppl): 297-308.
35. Tsutsui T, Suzuki N, Fukuda S, Sato M, Maizumi H, McLachlan JA, Berrett JC. 17β-estradiol induced cell transformation and aneuploidity of Syrian hamster embryo cells in culture. Carcinogenesis 1987; 8: 1715-9.
36. Kulling SE, Metzler M. Induction of micronuclei, DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestrogen coumoestrol. Food Chem Toxicol 1997; 35: 605-13.
37. Drevon C, Piccoli C, Montesano R. Mutagenicity assays of estrogenic hormones in mammalian cells. Mutat Res 1981; 89: 83-90.
38. Dwivedy I, Devanesan P, Cremonesi P, Rogan E, Cavalieri E. Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem Res Toxicol 1992; 5: 828-33.
39. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988; 85: 7831-5.
40. Nagasawa H, Mori T, Nakajima Y. Long-term effects of progesterone or diethylstilbestrol with or without estrogen after maturity on mammary tumorigenesis in mice. Eur J Cancer 1980; 16: 1583-9.
41. 3H mice by diets containing diethylstilbestrol or 17β-estradiol. J Environ Pathol Toxicol 1980; 4: 81-95.
42. Inoh A, Kamiya K, Fuji Y, Yokoro K. Protective effects of progesterone and tamoxifen in estrogen-induced mammary carcinogenesis in ovariectomized W/Fu rats. Jpn J Cancer Res 1985; 76: 699-704.
43. Noble RL, Hochachka BC, King D. Spontaneous and estrogen-produced tumors in Nb rats and their behaviour after transplantation. Cancer Res 1975; 35: 766-80.
44. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL. Ovary intact, but not ovariectomized female ACI rats treated with 17β-estradiol rapidly develop mammary carcinoma. Carcinogenesis 1997; 18: 1595-601.
45. Li JJ, Li SA, Klicka JK, Parsons JA, Lam LKT. Relative carcinogenic activity of various synthetic and natural estrogens in the Syrian hamster kidney. Cancer Res 1983; 43: 5200-4.
46. Li JJ, Li SA. Estrogen-induced tumorigenesis in hamsters: roles for hormonal and carcinogenic activities. Arch Toxicol 1984; 55: 110-8.
47. Liehr JG, Stancel GM, Chorich LP, Bousfield GR, Ulubelen AA. Hormonal carcinogenesis: separation of estrogenicity from carcinogenicity. Chem Biol Interact 1986; 59: 173-84.
48. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000; 21: 40-54.
49. Liehr JG. Modulation of estrogen-induced carcinogenesis by chemical modifications. Arch Toxicol 1984; 55: 119-22.
50. Welsch CW, Adams C, Lambrecht LK, Hassett CC, Brooks CL. 17β-oestradiol and Enovid mammary tumorigenesis in C3H/HeJ female mice: Counteraction by concurrent 2-bromo-α-ergocryptine. Br J Cancer 1977; 35: 322-8.
51. Ribeiro MF, Spritzer PM, Barbosa-Coutinho LM, Oliveira MC, Pavanato MA, Silva ISB, Reis FM. Effects of bromocriptine on serum prolactin in estradiol-treated ovariectomized rats: an experimental model of estrogen-dependent hyperprolactinemia. Braz J Med Biol Res 1997; 30: 113-7.
52. Liehr JG, Sirbasku DA, Jurka E, Randerath K, Randerath E. Inhibition of estrogen-induced renal carcinogenesis in male Syrian hamsters by tamoxifen without decrease in DNA adduct levels. Cancer Res 1988; 48: 779-83.
53. Topinka J, Andrae U, Schwarz LR, Wolff T. Cyproterone acetate generates DNA adducts in rat liver and in primary hepatocyte cultures. Carcinogenesis 1993; 14: 423-7.
54. Krebs O, Schäfer B, Wolff T, Oesterle D, Deml E, Sund M, Favor J. The DNA damaging drug cyproterone acetate causes gene mutations and induces glutathione-S-transferase P in the liver of female Big Blue™ transgenicF344 rats. Carcinogenesis 1998; 19: 241-5.
55. Martelli A, Mattioli F, Ghia M, Mereto E, Brambilla G. Comparative study of DNA repair induced by cyproterone acetate, chlormadinone acetate and megestrol acetate in primary cultures of human and rat hepatocytes. Carcinogenesis 1996; 17: 1153-6.
56. Swirsky Gold L, Stern BR, Slone TH, Brown JP, Manley NB, Ames BN. Pesticide residues in food: investigation of disparities in cancer risk estimates. Cancer Letters 1997; 117: 195-207.
57. Swirsky Gold L, Slone TH, Stern BR, Manley NB, Ames BN. Rodent carcinogens: setting priorities. Science 1992; 258: 261-5.
58. Ames BN, Magaw R, Swirsky Gold L. Ranking possible carcinogenic hazards Science 1987; 236: 271-80.
59. Friesen MD, Rothman N, Strickland PT. Concentration of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) in urine and alkali-hydrolyzed urine after consumption of charbroiled beef. Cancer Letters 2001; 173: 43-51.
60. Ames BN. Dietary carcinogens and anticarcinogens. Science 1983; 221: 1256-64.
61. Sugimura T, Sato S. Mutagens-carcinogens in foods. Cancer Res 1983; 43 (Suppl): 2415s-21s.